Skip to main content

Table 1 Human Tumor-Associated Antigens*

From: Ovarian cancer immunotherapy: opportunities, progresses and challenges

Antigen category

Antigens

Tumor type

Vaccine

Reference

Differentiation Antigens

Tyrosinase

Melanoma

Yes

Int J Cancer 1996;67:54[60]

 

Melan- Mart-1

Melanoma

Yes

Cancer J Sci Am 1997; 3:37[61]

 

gp-100

Melanoma

Yes

Nat Med 1998; 4:321[62]

Overexpression/Amplification

HER-2/neu

Ovarian cancer Breast cancer

Yes

J Clin Oncol. 2002; 20:2624[13]

Antigens

p53

various tumors

Yes

J Immunol 1998; 160:328[63]

Cancer Immunol Immunother. 2004; 53:633[64]

Mutational Antigens

p53

various tumors

Yes

J Clin Oncol 2005; 23:5099[65]

 

Ras

various tumors

Yes

Int J Cancer 2001; 92:441[66]

Cancer Testis Antigens

MAGE

Melanoma

Yes

Int J Cancer 1999; 80:219[67]

 

NY-ESO-1

Ovarian cancer

Yes

Clin Cancer Res. 2008; 14:2740[31]

 

LAGE-1

Ovarian cancer Melanoma Bladder cancer

No

Cancer Res. 2003; 63:6076[20]

Glycolipid Antigens

MUC-1

Adenocarcinoma

Yes

J. Clin. Invest. 1997; 100:2783[68]

 

MUC-16 (CA125)

Ovarian cancer

Yes

Int J Cancer 2002; 98:737[69]

Clin Cancer Res. 2004; 22:3507[70]

Oncofetal Antigens

AFP

Germ cell tumors

No

Gynecol. Oncol. 2000; 77:203[71]

 

CEA

Colorectal cancer

Yes

Ann Surg Oncol 1996; 3:495[72]

 

PSA

Prostate cancer

Yes

Urology 1999; 53:260[73]

Viral Antigens

HPV

Cervical cancer

Yes

Lancet 1996; 347:1523[74]

  1. *This represents only a partial list of tumor antigens for immunotherapy.